Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB4


Brief Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 4
Target Synonym:CD85k Antigen,Leukocyte immunoglobulin-like receptor 5,Immunoglobulin-like transcript 3,CD85k,CD85 antigen-like family member K,LIR-5,Monocyte inhibitory receptor HM18,ILT-3,Leucocyte Ig-Like Receptor B4,ILT3,LIR5,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4,HM18,Leukocyte Immunoglobulin Like Receptor B4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Human ANGPTL7, His Tag (Cat. No. AN7-H52H5) immobilized on CM5 Chip can bind Human LILRB4, His Tag (Cat. No. LI4-H52H7) with an affinity constant of 4.67 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Human LILRB4, Mouse IgG2a Fc Tag (Cat. No. LI4-H5257) at 1 μg/mL (100 μL/well) can bind Anti-LILRB4 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Synonym Name



Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
YTS-104 YTS-104; LILRB4 STAR-T Phase 1 Clinical China Immunotech Co Ltd, Beijing Qingyi Taike Pharmaceutical Technology Co Ltd Leukemia, Myeloid, Acute Details
NGM-831 NGM-831 Phase 1 Clinical Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
anti-ILT3 CAR-T Therapy(Carbiogene) Phase 1 Clinical Carbiogene Therapeutics Co Ltd Leukemia, Myeloid, Acute Details
IO-202 IO-202 Phase 1 Clinical Solid tumours; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute Details
MK-0482 MK-0482 Phase 2 Clinical Merck Sharp & Dohme Corp Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message